Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 EGFR-TK1-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients with NSCLC: When Is it Worth The Risk?

× No keyword cloud information.

5 in total

Review 1. EGFR TKI combination with immunotherapy in non-small cell lung cancer.

Authors: Myung-Ju Ahn; Jong-Mu Sun; Se-Hoon Lee; Jin Seok Ahn; Keunchil Park
Journal: Expert Opin Drug Saf Date: 2017-03-08 Impact factor: 4.250

2. Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC.

Authors: Scott Gettinger; Matthew D Hellmann; Laura Q M Chow; Hossein Borghaei; Scott Antonia; Julie R Brahmer; Jonathan W Goldman; David E Gerber; Rosalyn A Juergens; Frances A Shepherd; Scott A Laurie; Tina C Young; Xuemei Li; William J Geese; Naiyer Rizvi
Journal: J Thorac Oncol Date: 2018-05-23 Impact factor: 15.609

Review 3. Novel immunotherapy in the treatment of advanced non-small cell lung cancer.

Authors: G Santabarbara; P Maione; A Rossi; G Palazzolo; C Gridelli
Journal: Expert Rev Clin Pharmacol Date: 2016-09-23 Impact factor: 5.045

4. EGFR-TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non-Small Cell Lung Cancer.

Authors: Yasuo Oshima; Tetsuya Tanimoto; Koichiro Yuji; Arinobu Tojo
Journal: JAMA Oncol Date: 2018-08-01 Impact factor: 31.777

5. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.

Authors: K Haratani; H Hayashi; T Tanaka; H Kaneda; Y Togashi; K Sakai; K Hayashi; S Tomida; Y Chiba; K Yonesaka; Y Nonagase; T Takahama; J Tanizaki; K Tanaka; T Yoshida; K Tanimura; M Takeda; H Yoshioka; T Ishida; T Mitsudomi; K Nishio; K Nakagawa
Journal: Ann Oncol Date: 2017-07-01 Impact factor: 32.976

5 in total